One in every five strokes results from injury to perforating arteries and arterioles in the deeper, non-cortical parts of the cerebrum and brain stem. ' The mechanism of these lesions remains controversial2 4: some are haemorrhagic but most present post mortem as small black dots5-lacunae-due to infarction and subsequent cavitation. Until the present decade virtually all lacunar strokes were associated with hypertension,3 but the proportion has now declined to around 700' with the other 30," due to thromboembolism or hypoperfusion from occlusive extracranial vascular disease.' 6 A few lesions (35W') are asymptomatic but, because of their sensitive location, most (65°0)7 present as transient ischaemic attacks with stepwise deterioration or as a sudden, severe clinical deficit.8 The discrete nature of the lesion is often suggested by the absence of visual field defects, seizures, loss of consciousness, coma, combined motor and sensory deficits, apraxia, aphasia, or agnosia. Angiography does not disclose the affected vessel and the electroencephalographic pattern remains non-focal. In general the prognosis for recovery is excellent, and prolonged rehabilitation is rewarding.8
The recognition that small lesions (0. With pure motor hemiplegia, the lesion is usually in the posterior limb of the internal capsule, but similar manifestations may arise from infarction of the basis pontis. Although the CT scan is usually positive, cortical somatosensory evoked responses after stimulation of the median nerve may indicate a sensory, lemniscal lesion in some patients. 15 The close proximity of structures within the brain stem provides the setting for several lacunar syndromes. In the upper basis pontis the corticospinal fibres are dispersed into bundles, and lesions placed a few millimetres apart may cause either homolateral ataxia with crural paresis16 or facial weakness, severe dysarthria, and a clumsy hand.'7 Lacunar strokes can produce Weber's syndrome of unilateral third nerve palsy with contralateral hemiplegia, Claude's syndrome of cerebellar ataxia and crossed third nerve palsy, hemiballismus from a lesion of the subthalamic nucleus of Luys,8 and bilateral lesions of the ventral pons in the locked in syndrome.'8 Perhaps the most interesting symptom complex is the mesencephalothalamic syndrome resulting from an embolus at the top of the basilar artery-producing unilateral or bilateral third nerve palsies, paralysis of downward gaze, and drowsiness as a result of infarction in the territory of a perforating arteriole arising from the posterior cerebral artery.8
The impression that multi-infarct dementia results from repeated infarction-some symptomatic, some not-is probably erroneous. The initial lesion is almost always a symptomatic stroke,8 and more than three lacunar infarcts in one patient are rare.3 " Dementia is usually associated with bilaterally distributed infarcts,21' but sudden impairment of memory may follow unilateral infarction of the fornix and corpus callosum, and dementia may result from an infarct in the central region of the thalamus or subthalamus.8 21 Compliance with drug treatment is a problem in many branches of medicine but is not widely recognised as such in clinical oncology. Lewis et al have recently sought to broaden the concept of compliance from the traditional one of adherence by the patient to a prescribed oral regimen.' They cited the doctor's behaviour, the doctor-patient relationship, and the degree of psychosocial support available to the patient as important factors in determining how much of the intended dose was actually taken, and reviewed the data on the effect of these reductions in dose on outcome.
Assessment of individual compliance is limited by the lack of a simple urine test for most anticancer drugs and complicated by the frequent use of multidrug treatments. One study used assay of urinary 17-ketogenic steroids to determine compliance with treatment with prednisone in 52 patients with acute leukaemia. Some 30°o were found to be noncompliant, and this figure rose to 60°in the adolescent subgroup.2 Most other studies of compliance in patients with cancer have used the less reliable questionnaire approach.
Nausea and vomiting are probably the most frequent symptoms contributing to non-compliance, and there have been several recent attempts to refine antiemetic treatment.3 The control of severe "central" nausea and vomiting is still, however, far from perfect, and treatment will continue to cause many patients substantial distress.
The extent to which physicians' attitudes to adherence to the prescribed dose affect the doses actually administered has been studied in several multicentre trials. In the Medical Research Council study on advanced ovarian cancer, the protocol was substantially modified or abandoned as a result of toxicity in 44() ' , of 130 patients in the combination chemotherapy arm compared with only 14",, of 131 patients in the oral single agent arm.4 To these figures should be added the extent of non-compliance by the patient which could not be assessed in that study. A review of the National Surgical Adjuvant Breast Project study showed that about 30" of the patients failed to complete the two years of treatment. Furthermore, the variation in the incidence of gastrointestinal toxicity from institution to institution suggested substantial differences in the recognition of patients' complaints or the emphasis given to them. 5 Two studies from major cancer centres have looked at the effects on outcome of the reduction in dose by physicians. Bonnadonna and Valagussa analysed the reductions in dose in 238 patients given adjuvant combination chemotherapy for breast cancer.6 The five year survival of those who received more than 85(,, of the intended dose was 77") compared with 45( for those who received less than this dose level (p<0.0001). There was no observed relation between age and the reduction in dose due to toxicity. A more recent study from Stanford applied complex statistical analysis to data on 123 patients with Hodgkin's disease.7 The rate of drug delivery during the first three cycles of combination chemotherapy was found to be important in achieving a complete response. The rate of delivery of nitrogen mustard was the third most significant variable in predicting increased survival, after age and pleural disease.
In the past few years doctors have, rightly, become increasingly concerned about the quality of life for patients receiving cancer chemotherapy. Once the decision to treat has been taken, however, and the aim clearly defined as cure or palliation, undue concern for safety or acceptability should not be allowed to obscure the principal goal of efficacy. Review of the original decision or modification of the dose may be indicated more frequently in cases where treatment is given with palliative rather than curative intent. In human tumours neither the relation of dose to response nor its relation to toxicity is well understood, and reductions in dose have to be based on early toxicity assessed weeks, months, or years before any beneficial effect may be measured. Without doubt, however, the low therapeutic ratio of cancer treatments results in considerable variations in the way doctors and patients carry out a treatment policy-though most would accept the convention that in cancer treatment should usually be pushed to the limits of toxicity.8 In order that these limits may be more clearly defined, doctors who treat patients with cancer should be prepared to document the extent of and reasons for deviations from the particular treatment policy being followed. They should also be in a position to evaluate the defined end points of that treatment-usually response, interval free of disease, and survival-in terms of the treatment actually given and the toxicity encountered. 
